Medicus Pharma Ltd. (MDCX), a biotech/life sciences company, announced on Monday that its CEO had conducted a series of meetings with U.S. lawmakers, seeking support for the company's SkinJect product in treating Gorlin Syndrome.
Gorlin Syndrome, or nevoid basal cell carcinoma, is a rare, inherited disorder caused by mutations in the PTCH1 gene, dysregulating the Hedgehog pathway. This leads to early, recurrent tumor formations of over 1000 basal cell carcinomas, often beginning in childhood. The disease currently has no therapies approved by the U.S. Food and Drug Administration (FDA).
Medicus developed SkinJect as an immuno-oncological precision product for localized, repeat, non-surgical treatments of non-melanoma skin diseases.
The company's Chief Executive Officer, Raza Bokhari, engaged with lawmakers to discuss orphan drug designation for SkinJect, a registrational investigational new drug (IND) approval for Gorlin syndrome, in addition to a rare disease pediatric FDA voucher program.
Medicus previously announced a strategic collaboration with the Gorlin syndrome alliance (GSA) to advance access to SkinJect for the treatment of basal cell carcinomas.
MDCX is currently trading at $0.27, down 11.46%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.